{"filing":{"accession_number":"0001193125-26-312571","cik":"0001818794","ticker":"DYN","company_name":"Dyne Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"d112911d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526312571/d112911d8k.htm"},"events":[{"id":19683,"run_id":17709,"accession_number":"0001193125-26-312571","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Dyne Therapeutics announced the pricing of an upsized $375 million public offering of 18.3 million shares of common stock at $20.50 per share, with underwriters holding a 30-day option to purchase an additional 2.745 million shares.","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18848,"accession_number":"0001193125-26-312571","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.15,"reasoning":"This is an underwritten public offering of common stock (equity), not a debt issuance. The company is selling 18.3 million shares at $20.50 per share for approximately $375 million in gross proceeds. This is a dilutive equity issuance, not debt creation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:20:22.356891+00:00","company_name":"","ticker":null,"filing_date":""},{"id":18849,"accession_number":"0001193125-26-312571","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Dyne Therapeutics announced the pricing of an upsized $375 million public offering of 18.3 million shares of common stock at $20.50 per share, with an additional 30-day option for underwriters to purchase 2.745 million shares. This is a registered public offering of equity securities that will dilute existing shareholders. While technically a registered offering (not unregistered), the event is material to investors as it represents substantial capital raising through equity issuance and is the core disclosure in this Item 8.01 filing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:20:22.356891+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18848,"accession_number":"0001193125-26-312571","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.15,"reasoning":"This is an underwritten public offering of common stock (equity), not a debt issuance. The company is selling 18.3 million shares at $20.50 per share for approximately $375 million in gross proceeds. This is a dilutive equity issuance, not debt creation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:20:22.356891+00:00","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-07-22"},{"id":18849,"accession_number":"0001193125-26-312571","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Dyne Therapeutics announced the pricing of an upsized $375 million public offering of 18.3 million shares of common stock at $20.50 per share, with an additional 30-day option for underwriters to purchase 2.745 million shares. This is a registered public offering of equity securities that will dilute existing shareholders. While technically a registered offering (not unregistered), the event is material to investors as it represents substantial capital raising through equity issuance and is the core disclosure in this Item 8.01 filing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:20:22.356891+00:00","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-07-22"}]}